{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T05:34:49Z","timestamp":1738474489135,"version":"3.35.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.medine.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T16:48:42Z","timestamp":1722012522000},"page":"78-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Xa activity below range is related to thrombosis in patients with severe COVID-19"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-5280","authenticated-orcid":false,"given":"Pilar","family":"Marcos-Neira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0497-6003","authenticated-orcid":false,"given":"Cristian","family":"Morales-Indiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-4771","authenticated-orcid":false,"given":"Mariana","family":"Fern\u00e1ndez-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8033-8527","authenticated-orcid":false,"given":"Teresa","family":"Tomasa-Irriguible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-7309","authenticated-orcid":false,"given":"Luisa","family":"Bordej\u00e9-Laguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Ru\u00edz-Artola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.medine.2024.07.003_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.medine.2024.07.003_bib0010","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19-11 March 2020, https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020#:∼:text=WHO%20has%20been%20assessing%20this,to%20use%20lightly%20or%20carelessly; 2024 [accessed el 14 de abril 2024]."},{"issue":"3","key":"10.1016\/j.medine.2024.07.003_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000507039","article-title":"Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum","volume":"49","author":"Ronco","year":"2020","journal-title":"Blood Purif"},{"issue":"18","key":"10.1016\/j.medine.2024.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.medine.2024.07.003_bib0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"7","key":"10.1016\/j.medine.2024.07.003_bib0030","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis","volume":"18","author":"Panigada","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"7","key":"10.1016\/j.medine.2024.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1515\/cclm-2021-0108","article-title":"Thrombin generation in patients with COVID-19 with and without thromboprophylaxis","volume":"59","author":"Campello","year":"2021","journal-title":"Clin Chem Lab Med."},{"issue":"4","key":"10.1016\/j.medine.2024.07.003_bib0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10456-021-09805-6","article-title":"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects","volume":"24","author":"Smadja","year":"2021","journal-title":"Angiogenesis."},{"issue":"7","key":"10.1016\/j.medine.2024.07.003_bib0045","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year","volume":"8","author":"Leentjens","year":"2021","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.medine.2024.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"issue":"8","key":"10.1016\/j.medine.2024.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41379-021-00793-y","article-title":"Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience","volume":"34","author":"Bryce","year":"2021","journal-title":"Mod Pathol."},{"issue":"7","key":"10.1016\/j.medine.2024.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1055\/s-0040-1713152","article-title":"Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research","volume":"120","author":"Bikdeli","year":"2020","journal-title":"Thromb Haemost."},{"issue":"2","key":"10.1016\/j.medine.2024.07.003_bib0065","first-page":"135","article-title":"Set up of a protocol for heparin use in special patients","volume":"38","author":"Manresa Ram\u00f3n","year":"2014","journal-title":"Farm Hosp."},{"issue":"6","key":"10.1016\/j.medine.2024.07.003_bib0070","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann Pharmacother."},{"issue":"2","key":"10.1016\/j.medine.2024.07.003_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-009-0418-z","article-title":"Using low molecular weight heparin in special patient populations","volume":"29","author":"Lim","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.medine.2024.07.003_bib0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.medin.2021.08.011","article-title":"Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units","volume":"46","author":"Vidal-Cort\u00e9s","year":"2022","journal-title":"Med Intensiva (Engl Ed)"},{"issue":"9","key":"10.1016\/j.medine.2024.07.003_bib0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.medine.2024.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the ICU. The INSPIRATION randomized clinical trial","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.medine.2024.07.003_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J Thromb Thrombolysis."},{"issue":"6 Suppl","key":"10.1016\/j.medine.2024.07.003_bib0100","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"issue":"6 Suppl","key":"10.1016\/j.medine.2024.07.003_bib0105","doi-asserted-by":"crossref","first-page":"110S","DOI":"10.1378\/chest.08-0652","article-title":"Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.medine.2024.07.003_bib0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-020-02145-0","article-title":"Heparin resistance in COVID-19 patients in the intensive care unit","volume":"50","author":"White","year":"2020","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.medine.2024.07.003_bib0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.thromres.2021.07.010","article-title":"Pharmacokinetics of enoxaparin in COVID-19 critically ill patients","volume":"205","author":"Zufferey","year":"2021","journal-title":"Thromb Res."},{"issue":"3","key":"10.1016\/j.medine.2024.07.003_bib0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1164\/rccm.202005-1654LE","article-title":"Thromboprophylaxis in COVID-19: anti-FXa-the missing factor?","volume":"202","author":"Dutt","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.medine.2024.07.003_bib0125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.thromres.2020.09.039","article-title":"Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection","volume":"196","author":"Trunfio","year":"2020","journal-title":"Thromb Res."},{"issue":"6","key":"10.1016\/j.medine.2024.07.003_bib0130","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/0018578720954154","article-title":"Use of low-molecular-weight heparin and peak anti-Xa monitoring in severe SARS-CoV-2 disease: a brief report","volume":"56","author":"Toor","year":"2021","journal-title":"Hosp Pharm."},{"key":"10.1016\/j.medine.2024.07.003_bib0135","article-title":"Clinical experience in prophylactic enoxaparin dosage adjustment guided by anti-Xa factor levels in critical care patients with COVID-19 pneumonia: Observational study","author":"Del Carmen Berm\u00fadez-Ruiz","year":"2023","journal-title":"Med Intensiva."},{"issue":"20","key":"10.1016\/j.medine.2024.07.003_bib0140","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.medine.2024.07.003_bib0145","unstructured":"Good Clinical Practice Guidelines of the International Conference of Harmonization (2016), https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf; 2024 [accessed el 14 de abril 2024]."},{"key":"10.1016\/j.medine.2024.07.003_bib0150","unstructured":"General Data Protection Regulation (GDPR), https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32016R0679; 2024 [accessed el 14 de abril 2024]."},{"issue":"11","key":"10.1016\/j.medine.2024.07.003_bib0155","doi-asserted-by":"crossref","first-page":"e1087","DOI":"10.1097\/CCM.0000000000004548","article-title":"Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill Coronavirus Disease 2019 patients","volume":"48","author":"Taccone","year":"2020","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.medine.2024.07.003_bib0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/21548331.2020.1791541","article-title":"Antibiotic treatment in patients with sepsis: a narrative review","volume":"50","author":"Plata-Menchaca","year":"2022","journal-title":"Hosp Pract (1995)"},{"issue":"9309","key":"10.1016\/j.medine.2024.07.003_bib0165","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","article-title":"Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors","volume":"359","author":"D\u00f6rffler-Melly","year":"2002","journal-title":"Lancet."}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572724001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572724001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T03:16:39Z","timestamp":1738466199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572724001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2173572724001917"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2024.07.003","relation":{},"ISSN":["2173-5727"],"issn-type":[{"type":"print","value":"2173-5727"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Xa activity below range is related to thrombosis in patients with severe COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2024.06.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}